(Q41033340)

25 September 2017

Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities (English)

1 reference

25 September 2017

1 reference

5

1 reference

25 September 2017

8

1 reference

25 September 2017

Judith Niesen

1

1 reference

25 September 2017

Christoph Stein

2

1 reference

25 September 2017

Hannes Brehm

3

1 reference

25 September 2017

Grit Hehmann-Titt

4

1 reference

25 September 2017

Georg Melmer

6

1 reference

25 September 2017

Rainer Fischer

7

1 reference

25 September 2017

22 April 2015

1 reference

Journal of Cancer Research and Clinical Oncology

25 September 2017

1 reference

25 September 2017

141

1 reference

25 September 2017

12

1 reference

25 September 2017

2079-2095

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-015-1975-5

25 September 2017

0 references

cites work

scFv antibody: principles and clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Ligand-targeted therapeutics in anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Immunotoxins: the role of the toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Epithelioid and fibroblastic rat kidney cell clones: Epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Therapeutic targets and recent advances in protein immunotoxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Chemoprevention of breast cancer: a model for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Delivery into cells: lessons learned from plant and bacterial toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

The role of epidermal growth factor receptor in cancer metastasis and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

One target, different effects: a comparison of distinct therapeutic antibodies against the same targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Targeting the ERBB family in cancer: couples therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Development of antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-015-1975-5

Immunotoxin treatment of cancer

21 January 2018

1 reference

12 December 2020

The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.

1 reference

12 December 2020

Structure and function of epigen, the last EGFR ligand

1 reference

12 December 2020

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

1 reference

12 December 2020

Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer

1 reference

12 December 2020

A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins

1 reference

12 December 2020

In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor

1 reference

12 December 2020

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

1 reference

12 December 2020

Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon

1 reference

12 December 2020

Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.

1 reference

12 December 2020

Clonal analysis of a human antimouse antibody (HAMA) response

1 reference

12 December 2020

Immunotoxins for targeted cancer therapy

1 reference

12 December 2020

Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells

1 reference

12 December 2020

Technology evaluation: BL22, NCI.

1 reference

12 December 2020

Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.

1 reference

12 December 2020

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

12 December 2020

Antibodies to watch in 2014

1 reference

12 December 2020

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.

1 reference

12 December 2020

Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

1 reference

12 December 2020

In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells

1 reference

12 December 2020

10.1007/S00432-015-1975-5

Identifiers

DOI

1 reference

25 September 2017

1 reference